Zentalis Pharmaceuticals (ZNTL) Long-Term Deferred Tax (2019 - 2021)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Long-Term Deferred Tax of $716000.0 for Q2 2021, down 79.69% quarter-over-quarter from $3.5 million in Q1 2020.
Zentalis Pharmaceuticals (ZNTL) Long-Term Deferred Tax (2019 - 2021) Analysis & Trends
Zentalis Pharmaceuticals' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $716000.0 for Q2 2021.
- In Q2 2021, Long-Term Deferred Tax changed N/A year-over-year to $716000.0; the TTM figure through Jun 2021 stood at $716000.0 (changed N/A YoY), while the FY2019 annual figure was $841000.0, changed N/A from the prior year.
- Long-Term Deferred Tax for Q2 2021 stood at $716000.0, down from $3.5 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $3.5 million in Q1 2020, with the low at $716000.0 in Q2 2021.
- The 3-year median for Long-Term Deferred Tax is $841000.0 (2019), against an average of $1.7 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 716,000.00 |
| Mar 31, 2020 | 3.53 Mn |
| Dec 31, 2019 | 841,000.00 |